Clinical Trial Update: An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study [Phase 3]

View source ↗

Summary

An open-label extension study with long-term efficacy and safety monitoring for Crohn's disease patients previously treated with ustekinumab dose escalation aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Conditions: Crohn Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING